Revital Healthcare EPZ SA

by MMC
0 comment

Revital Healthcare EPZ Ltd., a leading medical device manufacturing company in Africa, announces a historic milestone in manufacturing excellence in Africa. The company is the first to obtain Pre-Qualification (PQ) status from the World Health Organization (WHO) on July 11, 2023 for its Early Activation Automatic Activation (AD) Syringe in Africa. This marks Revital’s more than decade-long commitment to injection safety in immunization programs across Africa.

The early activation feature is the gold standard for safety in immunization programs, preferred by UNICEF, and deactivates the syringe at the start of administration and injection. Historically, the introduction of these devices has led to a substantial reduction in the rates of blood-borne infections, such as HIV, in vaccination programs across Africa.

There are currently eight manufacturers that have WHO PQ status for this product, but Revital is the first and only one to be produced in Africa. This is expected to reduce average syringe transport times by up to 80-90% for Africa, which is essential for rapid outbreak response and timely vaccination campaigns.

Roneek Vora, Marketing and Sales Director of Revital Healthcare EPZ Ltd., comments: “Revital’s historic WHO pre-qualification for the Early Activation AD Syringe illustrates the transformative power of innovation and excellence of manufacturing in Africa. Our commitment to the well-being of our citizens, particularly children receiving life-saving vaccinations, is our motivation for continued progress.

Revital will be able to produce more than 300 million AD syringes per year.

This work was made possible by a grant from the Bill & Melinda Gates Foundation. In addition to supporting the development of this product to increase Africa’s security of supply, this has helped create over 200 new local jobs in Kilifi County, 80% of which are held by women, in support of a shared commitment to gender equality.

“As the first African manufacturer approved by WHO to produce self-activating and early activation syringes, Revital is paving the way for the expansion of local syringe production,” said Violaine Mitchell, Director of Immunization at the Bill & Melinda Gates Foundation.

“We are proud to support Revital’s efforts to sustainably increase the supply of these syringes in Africa and ensure vaccines are delivered safely and quickly across the continent. »

The WHO PQ list for the 0.5 ml early activation AD syringe can be accessed via the WHO Vaccine Quality Catalog.

You may also like

Leave a Comment

The news website dedicated to showcasing Africa news is a valuable platform that offers a diverse and comprehensive look into the continent’s latest developments. Covering everything from politics and economics to culture and wildlife conservation

u00a92022 All Right Reserved. Designed and Developed by PenciDesign